By Mill Chart
Last update: Oct 12, 2023
In this article we will dive into NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) as a possible candidate for growth investing. Investors should always do their own research, but we noticed NEUROCRINE BIOSCIENCES INC showing up in our strong growth, ready to breakout screen, which makes it worth to investigate a bit more.
ChartMill assigns a proprietary Growth Rating to each stock. The score is computed by evaluating various growth aspects, like EPS and revenue growth. We take into account the history as well as the estimated future numbers. NASDAQ:NBIX was assigned a score of 9 for growth:
A critical element of ChartMill's stock evaluation is the Health Rating, which spans from 0 to 10. This rating considers multiple health factors, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:NBIX has received a 7 out of 10:
ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NASDAQ:NBIX has earned a 8 out of 10:
Alongside the Technical Rating, ChartMill assigns a Setup Rating to evaluate the consolidation level of a stock. This rating, ranging from 0 to 10, is updated daily and considers various short-term technical indicators. The current setup rating for NASDAQ:NBIX is 9:
NBIX has an excellent technical rating and also presents a decent setup pattern. Prices have been consolidating lately. There is a resistance zone just above the current price starting at 116.37. Right above this resistance zone may be a good entry point. There is a support zone below the current price at 113.60, a Stop Loss order could be placed below this zone. Another positive sign is the recent Pocket Pivot signal.
More Strong Growth stocks can be found in our Strong Growth screener.
Our latest full fundamental report of NBIX contains the most current fundamental analsysis.
For an up to date full technical analysis you can check the technical report of NBIX
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
NEUROCRINE BIOSCIENCES INC
NASDAQ:NBIX (4/29/2024, 9:32:16 AM)
136.94
+0.95 (+0.7%)
Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser.
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of WHAT THE C@H?!, an educational initiative that aims to close the gap...
The economy is looking very strong and the biotech industry even more so, thus consider these top three stocks for strong profits.
The company is establishing its line-up of drugs behind bread-and-butter med Ingrezza.
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation.
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2024 financial results conference call and...
Looking for growth without the hefty price tag? Consider NASDAQ:NBIX.
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the first patient has been randomized for its Phase 2 clinical study to...
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 clinical study to evaluate the safety, tolerability,...
DexCom, Blackstone and Royal Caribbean head this list of five stocks.
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.